{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:07:09Z","timestamp":1789092429853,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The global incidence of thyroid cancer, particularly papillary thyroid carcinoma (PTC), is rising due to more frequent incidental findings. Despite a high 10-year survival rate of 93%, up to 28% of PTC patients experience locoregional recurrence. Postoperative monitoring typically relies on serum thyroglobulin (Tg), but the presence of anti-thyroglobulin antibodies (TgAb) interferes with Tg measurement, necessitating reliable detection methods. This study aimed to assess the predictive value of postoperative TgAb levels for PTC recurrence and establish a TgAb threshold as a prognostic marker.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>A retrospective analysis was conducted on 15,620 patients who underwent bilateral total thyroidectomies at Gangnam Severance Hospital between March 2004 and December 2022. After excluding patients with unmeasurable postoperative TgAb or other carcinoma types, the final cohort comprised 4,434 PTC patients (775 men and 3,659 women, median age 46\u2009\u00b1\u200911.68 years). Bilateral total thyroidectomy was performed on all patients. TgAb levels were measured 2 days post-surgery and annually, with the most recent levels used for analysis. The primary outcome was PTC recurrence, analyzed based on stratified TgAb levels.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Elevated TgAb levels were significantly associated with increased tumor size and recurrence rates (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Patients with TgAb levels above 440 IU\/mL showed a higher recurrence rate (13.3%) compared to those with lower levels. A TgAb threshold of 440 IU\/mL was identified as a novel recurrence marker, with an odds ratio of 6.0 (95% CI: 2.987\u201312.053, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). The disease-free survival (DFS) was shorter in patients with TgAb levels above this threshold.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Postoperative TgAb levels are a useful prognostic indicator for PTC recurrence, with a proposed threshold of 440 IU\/mL serving as a predictive marker. This threshold provides valuable insight for monitoring patients, irrespective of test timing post-surgery, and may guide clinical decision-making for identifying high-risk patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-14709-5","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T03:38:10Z","timestamp":1756093090000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anti-thyroglobulin antibody levels post-thyroidectomy and papillary thyroid carcinoma recurrence"],"prefix":"10.1186","volume":"25","author":[{"given":"Ho Jung","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Sung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeok Jun","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hojin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8070-0573","authenticated-orcid":false,"given":"Seok Mo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Sang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang-Seok","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"issue":"11","key":"14709_CR1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1089\/thy.2016.0100","volume":"26","author":"JJ Wiltshire","year":"2016","unstructured":"Wiltshire JJ, Drake TM, Uttley L, Balasubramanian SP. Systematic review of trends in the incidence rates of thyroid cancer. Thyroid. 2016;26(11):1541\u201352.","journal-title":"Thyroid"},{"issue":"12","key":"14709_CR2","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1","volume":"83","author":"SA Hundahl","year":"1998","unstructured":"Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National cancer data base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer: Interdisciplinary Int J Am Cancer Soc. 1998;83(12):2638\u201348.","journal-title":"Cancer: Interdisciplinary Int J Am Cancer Soc"},{"issue":"6","key":"14709_CR3","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.surg.2013.07.008","volume":"154","author":"RH Grogan","year":"2013","unstructured":"Grogan RH, Kaplan SP, Cao H, Weiss RE, DeGroot LJ, Simon CA, et al. A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. Surgery. 2013;154(6):1436\u201347.","journal-title":"Surgery"},{"issue":"8","key":"14709_CR4","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1210\/jc.2004-0986","volume":"89","author":"CA Spencer","year":"2004","unstructured":"Spencer CA. Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metabolism. 2004;89(8):3702\u20134.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"2","key":"14709_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1046\/j.1365-2265.2003.01681.x","volume":"58","author":"L Demers","year":"2003","unstructured":"Demers L, Spencer CA. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Clin Endocrinol. 2003;58(2):138\u201340.","journal-title":"Clin Endocrinol"},{"issue":"12","key":"14709_CR6","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1210\/jc.2014-1203","volume":"99","author":"C Spencer","year":"2014","unstructured":"Spencer C, Petrovic I, Fatemi S, LoPresti J. Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (Second-Generation) immunometric assays can be disrupted by False-Negative and False-Positive serum thyroglobulin autoantibody misclassifications. J Clin Endocrinol Metabolism. 2014;99(12):4589\u201399.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"14709_CR7","doi-asserted-by":"crossref","unstructured":"HaugenBryan R, AlexanderErik K, BibleKeith C, DohertyGerard M, MandelSusan J, NikiforovYuri E et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):66\u201368.","DOI":"10.1089\/thy.2015.0020"},{"issue":"3","key":"14709_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1530\/acta.0.1190373","volume":"119","author":"F Pacini","year":"1988","unstructured":"Pacini F, Mariotti S, Formica N, Elisei R, Anelli S, Capotorti E, et al. Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. Eur J Endocrinol. 1988;119(3):373\u201380.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"14709_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1089\/thy.1994.4.199","volume":"4","author":"A Kumar","year":"1994","unstructured":"Kumar A, Shah DH, Shrihari U, Dandekar SR, Vijayan U, Sharma SM. Significance of antithyroglobulin autoantibodies in differentiated thyroid carcinoma. Thyroid. 1994;4(2):199\u2013202.","journal-title":"Thyroid"},{"issue":"8","key":"14709_CR10","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1089\/thy.2009.0384","volume":"20","author":"ES Kim","year":"2010","unstructured":"Kim ES, Lim DJ, Baek KH, Lee JM, Kim MK, Kwon HS, et al. Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules. Thyroid. 2010;20(8):885\u201391.","journal-title":"Thyroid"},{"issue":"8","key":"14709_CR11","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1089\/thy.2010.1651","volume":"20","author":"SK Grebe","year":"2010","unstructured":"Grebe SK. Thyroglobulin autoantibodies, thyroid nodules, and new insights into some old questions. Thyroid. 2010;20(8):841\u20133.","journal-title":"Thyroid"},{"issue":"8","key":"14709_CR12","first-page":"1478","volume":"33","author":"D Rubello","year":"1992","unstructured":"Rubello D, Casara D, Girelli ME, Piccolo M, Busnardo B. Clinical meaning of Circulating anti-thyroglobulin antibodies in differentiated thyroid cancer: a prospective study. J Nucl Med. 1992;33(8):1478\u201380.","journal-title":"J Nucl Med"},{"issue":"7","key":"14709_CR13","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1089\/thy.2013.0698","volume":"24","author":"C Durante","year":"2014","unstructured":"Durante C, Tognini S, Montesano T, Orlandi F, Torlontano M, Puxeddu E, et al. Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and Circulating anti-thyroglobulin autoantibodies. Thyroid. 2014;24(7):1139\u201345.","journal-title":"Thyroid"},{"issue":"1","key":"14709_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1530\/eje.1.01940","volume":"153","author":"R Gorges","year":"2005","unstructured":"Gorges R, Maniecki M, Jentzen W, Mann K, Bockisch A, Janssen O. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol. 2005;153(1):49\u201355.","journal-title":"Eur J Endocrinol"},{"issue":"5Part1","key":"14709_CR15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.7326\/0003-4819-139-5_Part_1-200309020-00010","volume":"139","author":"L Chiovato","year":"2003","unstructured":"Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med. 2003;139(5Part1):346\u201351.","journal-title":"Ann Intern Med"},{"issue":"12","key":"14709_CR16","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1210\/jc.2008-0962","volume":"93","author":"WG Kim","year":"2008","unstructured":"Kim WG, Yoon JH, Kim WB, Kim TY, Kim EY, Kim JM, et al. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metabolism. 2008;93(12):4683\u20139.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"5","key":"14709_CR17","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.beem.2013.07.003","volume":"27","author":"C Spencer","year":"2013","unstructured":"Spencer C, Fatemi S. Thyroglobulin antibody (TgAb) methods\u2013strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab. 2013;27(5):701\u201312.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"7","key":"14709_CR18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1507\/endocrj.EJ12-0410","volume":"60","author":"Y Tsushima","year":"2013","unstructured":"Tsushima Y, Miyauchi A, Ito Y, Kudo T, Masuoka H, Yabuta T, et al. Prognostic significance of changes in serum thyroglobulin antibody levels of pre-and post-total thyroidectomy in thyroglobulin antibody-positive papillary thyroid carcinoma patients. Endocr J. 2013;60(7):871\u20136.","journal-title":"Endocr J"},{"issue":"10","key":"14709_CR19","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1507\/endocrj.EJ14-0275","volume":"61","author":"O Yamada","year":"2014","unstructured":"Yamada O, Miyauchi A, Ito Y, Nakayama A, Yabuta T, Masuoka H, et al. Changes in serum thyroglobulin antibody levels as a dynamic prognostic factor for early-phase recurrence of thyroglobulin antibody-positive papillary thyroid carcinoma after total thyroidectomy. Endocr J. 2014;61(10):961\u20135.","journal-title":"Endocr J"},{"issue":"3","key":"14709_CR20","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1089\/thy.2012.0611","volume":"24","author":"C-J Hsieh","year":"2014","unstructured":"Hsieh C-J, Wang P-W. Sequential changes of serum antithyroglobulin antibody levels are a good predictor of disease activity in thyroglobulin-negative patients with papillary thyroid carcinoma. Thyroid. 2014;24(3):488\u201393.","journal-title":"Thyroid"},{"key":"14709_CR21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1590\/S0004-27302004000400008","volume":"48","author":"PWS Ros\u00e1rio","year":"2004","unstructured":"Ros\u00e1rio PWS, Maia FFR, Fagundes TA, Vasconcelos FP, Cardoso LD, Purisch S. Antithyroglobulin antibodies in patients with differentiated thyroid carcinoma: methods of detection, interference with serum thyroglobulin measurement and clinical significance. Arquivos Brasileiros De Endocrinologia Metabologia. 2004;48:487\u201392.","journal-title":"Arquivos Brasileiros De Endocrinologia Metabologia"},{"issue":"9","key":"14709_CR22","first-page":"504","volume":"13","author":"A Adil","year":"2003","unstructured":"Adil A, Jafri RA, Waqar A, Abbasi SA, Asghar A, Jilani A, et al. Frequency and clinical importance of anti-Tg auto-antibodies (ATG). J Coll Physicians Surgeons\u2013pakistan: JCPSP. 2003;13(9):504\u20136.","journal-title":"J Coll Physicians Surgeons\u2013pakistan: JCPSP"},{"issue":"2","key":"14709_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1046\/j.1365-2265.2002.01592.x","volume":"57","author":"JK Chung","year":"2002","unstructured":"Chung JK, Park Y, Kim T, So Y, Kim SK, Park D, et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol. 2002;57(2):215\u201321.","journal-title":"Clin Endocrinol"},{"issue":"1","key":"14709_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1530\/EJE-07-0399","volume":"158","author":"HT Phan","year":"2008","unstructured":"Phan HT, Jager PL, van der Wal JE, Sluiter WJ, Plukker JT, Dierckx RA, et al. The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. Eur J Endocrinol. 2008;158(1):77\u201383.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"14709_CR25","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1053\/clon.1999.9056","volume":"11","author":"P Hjiyiannakis","year":"1999","unstructured":"Hjiyiannakis P, Mundy J, Harmer C. Thyroglobulin antibodies in differentiated thyroid cancer. Clin Oncol. 1999;11(4):240\u20134.","journal-title":"Clin Oncol"},{"issue":"2","key":"14709_CR26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4067\/S0034-98872002000200006","volume":"130","author":"I Quevedo","year":"2002","unstructured":"Quevedo I, Campino C, JA RP, Arteaga E, L\u00f3pez JM, Campusano C, et al. Anti thyroglobulin antibodies in the follow up of patients with differentiated thyroid cancer: residual or relapsing disease markers? Revista M\u00e9dica De Chile. 2002;130(2):167\u201372.","journal-title":"Revista M\u00e9dica De Chile"},{"issue":"4","key":"14709_CR27","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1365-2265.2009.03693.x","volume":"72","author":"JH Seo","year":"2010","unstructured":"Seo JH, Lee SW, Ahn BC, Lee J. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using 18F-FDG PET\/CT. Clin Endocrinol. 2010;72(4):558\u201363.","journal-title":"Clin Endocrinol"},{"issue":"10","key":"14709_CR28","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1097\/MNM.0b013e328308e079","volume":"29","author":"G Aras","year":"2008","unstructured":"Aras G, G\u00fcltekin SS, K\u00fc\u00e7\u00fck N\u00d6. The additive clinical value of combined thyroglobulin and antithyroglobulin antibody measurements to define persistent and recurrent disease in patients with differentiated thyroid cancer. Nucl Med Commun. 2008;29(10):880\u20134.","journal-title":"Nucl Med Commun"},{"key":"14709_CR29","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/BF03349612","volume":"13","author":"D Rubello","year":"1990","unstructured":"Rubello D, Girelli M, Casara D, Piccolo M, Perin A, Busnardo B. Usefulness of the combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Investig. 1990;13:737\u201342.","journal-title":"J Endocrinol Investig"},{"issue":"2","key":"14709_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/thy.2006.16.109","volume":"16","author":"DS Cooper","year":"2006","unstructured":"Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines taskforce. Thyroid. 2006;16(2):109\u201342.","journal-title":"Thyroid"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14709-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14709-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14709-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:02:54Z","timestamp":1757455374000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14709-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14709"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14709-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Institutional Review Board (IRB) of Gangnam Severance Hospital, Yonsei University College of Medicine (approval number: 3-2024-0013). The requirement for informed consent was waived by the Institutional Review Board (IRB) of Gangnam Severance Hospital, Yonsei University College of Medicine in accordance with national regulations and institutional policies due to the retrospective nature of the study. All study procedures complied with the ethical standards of the institutional and national research committee, as well as the 1964 Helsinki Declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1371"}}